Genmab AS (GMAB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3723032062
Genmab AS financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 3.12 bn USD | 3.72 bn USD |
| Gross profit | 2.98 bn USD | 3.48 bn USD |
| Operating income | – | 1.07 bn USD |
| EBIT | 971.38 m USD | 1.25 bn USD |
| Net income | 1.13 bn USD | 963.00 m USD |
| Diluted EPS – continuing operations | 12.23 USD | 1.43 USD |
Full history since 2002, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
More stocks
- Oersted A/S (ORSTED.CO)
- Pop Mart International Group Ltd (9992.HK)
- Singapore Technologies Engineering Ltd (S63.SI)
- InterContinental Hotels Group PLC (IHG.L)
- Klabin S.A. (KLBN11.SA)
- CLP Holdings Ltd (2.HK)
- Eversource Energy (ES)
- F5 Networks Inc (FFIV.MX)
- Bandai Namco Holdings Inc (7832.T)
- Yushu Technology (688836.SS)
- Zai Lab Ltd (ZLAB)
- Affirm Holdings, Inc. (AFRM)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.